{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362262943667966336.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1093/jjco/hyy179"}},{"identifier":{"@type":"URI","@value":"http://academic.oup.com/jjco/article-pdf/49/1/29/27565507/hyy179.pdf"}},{"identifier":{"@type":"PMID","@value":"30508196"}}],"dc:title":[{"@value":"Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset"}],"description":[{"notation":[{"@value":"The FLAURA study was a multicenter, double-blind, Phase 3 study in which patients with previously untreated epidermal growth factor receptor mutation-positive advanced non-small-cell lung carcinoma were randomized 1:1 to oral osimertinib 80 mg once daily or standard-of-care (gefitinib 250 mg or erlotinib 150 mg, once daily) to compare safety and efficacy. In the overall FLAURA study, significantly better progression-free survival was shown with osimertinib versus standard-of-care.Selected endpoints, including progression-free survival (primary endpoint), overall survival, objective response rate, duration of response and safety were evaluated for the Japanese subset of the FLAURA study.In Japan, 120 eligible Japanese patients were randomized to osimertinib (65 patients) or gefitinib (55 patients) treatment from December 2014 to June 2017. Median progression-free survival was 19.1 (95% confidence interval, 12.6, 23.5) and 13.8 (95% confidence interval, 8.3, 16.6) months with osimertinib and gefitinib, respectively (hazard ratio, 0.61; 95% confidence interval, 0.38, 0.99). Median overall survival was not reached in either treatment arm (data were immature). In the osimertinib and gefitinib arms, objective response rate was 75.4% (49/65) and 76.4% (42/55), and median duration of response from onset was 18.4 (95% confidence interval, not calculated) and 9.5 (95% confidence interval, 6.2, 13.9) months, respectively. The incidence of adverse events was similar in the two groups. The frequency of Grade ≥3 interstitial lung disease and pneumonitis in the two groups were the same (one patient).As the first-line therapy, osimertinib showed significantly improved efficacy versus gefitinib in the Japanese population of the FLAURA study. No new safety concerns were raised.NCT02296125 (ClinicalTrials.gov)."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382262943667966337","@type":"Researcher","foaf:name":[{"@value":"Yuichiro Ohe"}],"jpcoar:affiliationName":[{"@value":"Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943667966464","@type":"Researcher","foaf:name":[{"@value":"Fumio Imamura"}],"jpcoar:affiliationName":[{"@value":"Department of Thoracic Oncology, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943667966340","@type":"Researcher","foaf:name":[{"@value":"Naoyuki Nogami"}],"jpcoar:affiliationName":[{"@value":"Department of Thoracic Oncology, National Hospital Organization Shikoku Cancer Center, Minamiumemoto-machi, Matsuyama, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943667966336","@type":"Researcher","foaf:name":[{"@value":"Isamu Okamoto"}],"jpcoar:affiliationName":[{"@value":"Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943667966467","@type":"Researcher","foaf:name":[{"@value":"Takayasu Kurata"}],"jpcoar:affiliationName":[{"@value":"Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Osaka, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943667966471","@type":"Researcher","foaf:name":[{"@value":"Terufumi Kato"}],"jpcoar:affiliationName":[{"@value":"Department of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Kanazawa-ku, Yokohama, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943667966338","@type":"Researcher","foaf:name":[{"@value":"Shunichi Sugawara"}],"jpcoar:affiliationName":[{"@value":"Department of Pulmonary Medicine, Sendai Kousei Hospital, Aoba-ku, Sendai, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943667966465","@type":"Researcher","foaf:name":[{"@value":"Suresh S Ramalingam"}],"jpcoar:affiliationName":[{"@value":"Winship Cancer Institute, Emory University, Atlanta, GA, USA"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943667966468","@type":"Researcher","foaf:name":[{"@value":"Hirohiko Uchida"}],"jpcoar:affiliationName":[{"@value":"Research and Development, AstraZeneca K.K., Grand Front Osaka Tower B, Kita-ku, Osaka, Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943667966339","@type":"Researcher","foaf:name":[{"@value":"Rachel Hodge"}],"jpcoar:affiliationName":[{"@value":"AstraZeneca, Cambridge, da Vinci Building, Melbourn Science Park, Melbourn, Cambridgeshire, UK"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943667966466","@type":"Researcher","foaf:name":[{"@value":"Sarah L Vowler"}],"jpcoar:affiliationName":[{"@value":"AstraZeneca, Cambridge, da Vinci Building, Melbourn Science Park, Melbourn, Cambridgeshire, UK"}]},{"@id":"https://cir.nii.ac.jp/crid/1382262943667966469","@type":"Researcher","foaf:name":[{"@value":"Andrew Walding"}],"jpcoar:affiliationName":[{"@value":"AstraZeneca, Cambridge, da Vinci Building, Melbourn Science Park, Melbourn, Cambridgeshire, UK"}]},{"@id":"https://cir.nii.ac.jp/crid/1420282801196990976","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"40298964"},{"@type":"NRID","@value":"1000040298964"},{"@type":"NRID","@value":"9000006828515"},{"@type":"NRID","@value":"9000016862696"},{"@type":"NRID","@value":"9000387919539"},{"@type":"NRID","@value":"9000253365379"},{"@type":"NRID","@value":"9000007693601"},{"@type":"NRID","@value":"9000366124111"},{"@type":"NRID","@value":"9000001021796"},{"@type":"NRID","@value":"9000020177896"},{"@type":"NRID","@value":"9000002408370"},{"@type":"NRID","@value":"9000243884356"},{"@type":"NRID","@value":"9000392751828"},{"@type":"NRID","@value":"9000014163756"},{"@type":"NRID","@value":"9000382635292"},{"@type":"NRID","@value":"9000409650318"},{"@type":"NRID","@value":"9000312825461"},{"@type":"NRID","@value":"9000253618155"},{"@type":"NRID","@value":"9000392739673"},{"@type":"NRID","@value":"9000018682986"},{"@type":"NRID","@value":"9000016257425"},{"@type":"NRID","@value":"9000414490919"},{"@type":"NRID","@value":"9000253208805"},{"@type":"NRID","@value":"9000359880229"},{"@type":"NRID","@value":"9000001225535"},{"@type":"NRID","@value":"9000261040392"},{"@type":"NRID","@value":"9000009915189"},{"@type":"NRID","@value":"9000020880081"},{"@type":"NRID","@value":"9000258109910"},{"@type":"NRID","@value":"9000364096839"},{"@type":"NRID","@value":"9000021410362"},{"@type":"NRID","@value":"9000021222848"},{"@type":"NRID","@value":"9000252851116"},{"@type":"NRID","@value":"9000403020456"},{"@type":"NRID","@value":"9000000482237"},{"@type":"NRID","@value":"9000286630960"},{"@type":"NRID","@value":"9000253110253"},{"@type":"NRID","@value":"9000253344705"},{"@type":"NRID","@value":"9000255748940"},{"@type":"NRID","@value":"9000014529607"},{"@type":"NRID","@value":"9000021609005"},{"@type":"NRID","@value":"9000021378342"},{"@type":"NRID","@value":"9000367430086"},{"@type":"NRID","@value":"9000253401957"},{"@type":"NRID","@value":"9000392749839"},{"@type":"NRID","@value":"9000367826898"},{"@type":"NRID","@value":"9000005277137"},{"@type":"NRID","@value":"9000398606921"},{"@type":"NRID","@value":"9000251867706"},{"@type":"NRID","@value":"9000018465163"},{"@type":"NRID","@value":"9000002201529"},{"@type":"NRID","@value":"9000020324676"},{"@type":"NRID","@value":"9000410651895"},{"@type":"NRID","@value":"9000253618788"},{"@type":"NRID","@value":"9000392001590"},{"@type":"NRID","@value":"9000001993903"},{"@type":"NRID","@value":"9000413480036"},{"@type":"NRID","@value":"9000365543620"},{"@type":"NRID","@value":"9000253208822"},{"@type":"NRID","@value":"9000254179348"},{"@type":"NRID","@value":"9000391592745"},{"@type":"NRID","@value":"9000398273221"},{"@type":"NRID","@value":"9000399747830"},{"@type":"NRID","@value":"9000399797615"},{"@type":"NRID","@value":"9000018719011"},{"@type":"NRID","@value":"9000014416413"},{"@type":"NRID","@value":"9000365539011"},{"@type":"NRID","@value":"9000242079164"},{"@type":"NRID","@value":"9000415325683"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/Nakagawa_Kazuhiko"}],"foaf:name":[{"@value":"Kazuhiko Nakagawa"}],"jpcoar:affiliationName":[{"@value":"Department of Medical Oncology, Kindai University Hospital, Ohno-higashi, Osaka, Japan"}]}],"publication":{"publicationIdentifier":[{"@type":"EISSN","@value":"14653621"}],"prism:publicationName":[{"@value":"Japanese Journal of Clinical Oncology"}],"dc:publisher":[{"@value":"Oxford University Press (OUP)"}],"prism:publicationDate":"2018-12-01","prism:volume":"49","prism:number":"1","prism:startingPage":"29","prism:endingPage":"36"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["http://creativecommons.org/licenses/by-nc/4.0/"],"url":[{"@id":"http://academic.oup.com/jjco/article-pdf/49/1/29/27565507/hyy179.pdf"}],"createdAt":"2018-11-26","modifiedAt":"2019-01-21","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Acrylamides","dc:title":"Acrylamides"},{"@id":"https://cir.nii.ac.jp/all?q=Aniline%20Compounds","dc:title":"Aniline Compounds"},{"@id":"https://cir.nii.ac.jp/all?q=Lung%20Neoplasms","dc:title":"Lung Neoplasms"},{"@id":"https://cir.nii.ac.jp/all?q=Antineoplastic%20Agents","dc:title":"Antineoplastic Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Piperazines","dc:title":"Piperazines"},{"@id":"https://cir.nii.ac.jp/all?q=Progression-Free%20Survival","dc:title":"Progression-Free Survival"},{"@id":"https://cir.nii.ac.jp/all?q=ErbB%20Receptors","dc:title":"ErbB Receptors"},{"@id":"https://cir.nii.ac.jp/all?q=Japan","dc:title":"Japan"},{"@id":"https://cir.nii.ac.jp/all?q=Carcinoma,%20Non-Small-Cell%20Lung","dc:title":"Carcinoma, Non-Small-Cell Lung"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Original%20Article","dc:title":"Original Article"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Protein%20Kinase%20Inhibitors","dc:title":"Protein Kinase Inhibitors"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050013861702263936","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"TAPO in first-line osimertinib therapy and continuation of osimertinib"},{"@value":"<scp>TAPO</scp> in first‐line osimertinib therapy and continuation of osimertinib"}]},{"@id":"https://cir.nii.ac.jp/crid/1360009142921873152","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical course and prognosis of patients with lung cancer who develop anticancer therapy-related pneumonitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360021390578522112","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302865745268480","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Multi-institutional study of osimertinib dose-optimization in non-small cell lung cancer patients with EGFR activating mutation aged 70 years or older (‘MONEY’ trial)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302866850572416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring <i>EGFR</i> mutation: an observational clinical study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360579819983370240","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360580229814436224","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"First-line therapy in non-small cell lung cancer patients with <i>EGFR</i> activating mutations: a consideration of the clinical position of osimertinib based on the subset of Japanese patients in the FLAURA study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584340532894592","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Factors associated with lenvatinib adherence in thyroid cancer and hepatocellular carcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360588381074128640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study)"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567575120256","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Quantification of BIM mRNA in circulating tumor cells of osimertinib-treated patients with EGFR mutation-positive lung cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593781300096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857593789482752","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)"}]},{"@id":"https://cir.nii.ac.jp/crid/1361975841941001728","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations"}]},{"@id":"https://cir.nii.ac.jp/crid/1390293257457252864","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A Study of the Relationship Between Interstitial Lung Abnormalities and Osimertinib-induced Lung Injury"},{"@language":"ja","@value":"Interstitial lung abnormalitiesとオシメルチニブによる薬剤性肺障害との関連に関する検討"}]},{"@id":"https://cir.nii.ac.jp/crid/1390296288050848256","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Upfront Use of First-/Second-Generation EGFR-TKI Followed by Osimertinib Shows Better Prognosis than Upfront Osimertinib Therapy in Japanese Patients with Non-small-cell Lung Cancer with Exon 19 Deletion: A Single-Center Retrospective Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1390305201349328640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Successful Switch to Afatinib and Osimertinib Rechallenge with Corticosteroids after Osimertinib-induced Interstitial Lung Disease: A Case Report and Literature Review"}]},{"@id":"https://cir.nii.ac.jp/crid/1390565134811337728","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Successful Osimertinib Rechallenge After Osimertinib-induced Interstitial Lung Disease in a Patient with Postoperative Recurrence of Lung Cancer"},{"@language":"ja","@value":"薬剤性間質性肺炎発症後にステロイド内服下でのオシメルチニブ再投与が可能であった肺癌術後再発の1例"}]},{"@id":"https://cir.nii.ac.jp/crid/1390582075820246016","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Two Cases of EGFR-mutated Non-small-cell Lung Cancer Treated with Erlotinib+Ramucirumab After Osimertinib-induced Lung Injury"},{"@language":"ja","@value":"オシメルチニブ肺障害後にエルロチニブ＋ラムシルマブで治療を行ったEGFR遺伝子変異陽性非小細胞肺癌の2例"}]},{"@id":"https://cir.nii.ac.jp/crid/1390866345576842240","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Successful Treatment with Ramucirumab Plus Erlotinib following Osimertinib-induced Interstitial Lung Disease"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1093/jjco/hyy179"},{"@type":"OPENAIRE","@value":"doi_dedup___::7170552ae331f96ee6df534d92993632"},{"@type":"CROSSREF","@value":"10.1007/s00432-020-03478-2_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.1248/bpb.b22-00794_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.1016/j.chest.2022.05.035_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.1016/j.ejca.2023.02.023_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.2482/haigan.59.1184_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.2482/haigan.64.186_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.1093/jjco/hyae032_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.1177/17588359231177021_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.4877-24_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.2482/haigan.62.292_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.1093/jjco/hyac012_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0294320_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.1016/j.jtocrr.2024.100720_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.1016/j.resinv.2021.03.010_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.1016/j.ejca.2021.02.019_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.1016/j.ejca.2021.09.041_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.1111/1759-7714.14782_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.3932-24_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"},{"@type":"CROSSREF","@value":"10.1016/j.lungcan.2019.11.012_references_DOI_AZ8zQII4BazbprhXfIoq63g2Qwk"}]}